ARCHIVES

Phase II Elotuzumab Study Demonstrates 33 Months PFS

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Wyden, Schroeder Bill Would Require NIH To Test RU 486

October 23, 1992

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

March 28, 2014

DCBDC Advisors Set aside $2 Mil. For Research On The Microenvironment of Breast Cancer

July 9, 1993

Long-Term Remissions Shown With Chemo Plus Radiation

September 29, 2006

Four Win 1988 General Motors Cancer Prizes

June 17, 1988

In Brief: Fauci, Washington Univ. Chancellor, Merck Chairman Reportedly On Final NIH Director List

August 25, 1989